Gene · 1890
Papers4,467
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 4,467
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment. | Int J Nanomedicine | 2023 | 38059000 | PubTator, text mining | PubMed |
| Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma. | Technol Cancer Res Treat | 2023 | 38043946 | PubTator, text mining | PubMed |
| Proteome profiling identifies circulating biomarkers associated with hepatic steatosis in subjects with Prader-Willi syndrome. | Front Endocrinol (Lausanne) | 2023 | 38034016 | PubTator, text mining | PubMed |
| PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. | Nat Commun | 2023 | 38030622 | PubTator, text mining | PubMed |
| A combined crystallographic and theoretical investigation of noncovalent interactions in 1,3,4-oxadiazole-2-thione-N-Mannich derivatives: in vitro bioactivity and molecular docking. | RSC Adv | 2023 | 38019986 | PubTator, text mining | PubMed |
| Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment. | Molecules | 2023 | 38005235 | PubTator, text mining | PubMed |
| Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients. | Pharmaceutics | 2023 | 38004528 | PubTator, text mining | PubMed |
| The Risk of Venous Thromboembolism in Neuroendocrine Neoplasms. | Cancers (Basel) | 2023 | 38001737 | PubTator, text mining | PubMed |
| Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer. | ESMO Open | 2023 | 37977001 | PubTator, text mining | PubMed |
| Investigation of novel bis-thiadiazole bearing schiff base derivatives as effective inhibitors of thymidine phosphorylase: Synthesis, in vitro bioactivity and molecular docking study. | Saudi Pharm J | 2023 | 37965293 | PubTator, text mining | PubMed |
| Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patients' Outcome. | Cancers (Basel) | 2023 | 37958298 | PubTator, text mining | PubMed |
| Functional Proteomics Characterization of the Role of SPRYD7 in Colorectal Cancer Progression and Metastasis. | Cells | 2023 | 37947626 | PubTator, text mining | PubMed |
| The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity. | Hum Genomics | 2023 | 37946254 | PubTator, text mining | PubMed |
| Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. | BMC Cancer | 2023 | 37940878 | PubTator, text mining | PubMed |
| Astrogliosis in multiple sclerosis and neuro-inflammation: what role for the notch pathway? | Front Immunol | 2023 | 37936690 | PubTator, text mining | PubMed |
| Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. | Nat Commun | 2023 | 37903821 | PubTator, text mining | PubMed |
| Special Issue "Hybrid Drugs: Design and Applications". | Pharmaceuticals (Basel) | 2023 | 37895829 | PubTator, text mining | PubMed |
| Plant Extracts as Skin Care and Therapeutic Agents. | Int J Mol Sci | 2023 | 37895122 | PubTator, text mining | PubMed |
| Design, Synthesis, In Vitro Biological Evaluation and In Silico Molecular Docking Study of Benzimidazole-Based Oxazole Analogues: A Promising Acetylcholinesterase and Butyrylcholinesterase Inhibitors. | Molecules | 2023 | 37894494 | PubTator, text mining | PubMed |
| Analysis of proteins released from osteoarthritic cartilage by compressive loading. | Sci Rep | 2023 | 37880329 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1890/papers?page=10